arginylation regulates striated muscle function. Exerc. Sport Sci. Rev., Vol. 44, No. 3, pp. 98-103, 2016. In this article, we propose the hypothesis that the posttranslational arginylation of proteins, a process catalyzed by the enzyme arginyl-tRNA-transferase, regulates active and passive force generation in striated muscles. Specifically, we propose that proteins essential for muscle contraction and force production are regulated by arginylation, including myosin heavy chain, troponin, actin, and titin filaments.
INTRODUCTION
Posttranslational arginylation is a process catalyzed by the enzyme arginyl-tRNA-transferase (ATE1), in which amino acid arginine is transferred from tRNA to proteins in a ribosomeindependent manner. Protein arginylation is associated with several critical cellular functions such as embryogenesis, cell migration, and aging (12, 16, 18) . Furthermore, arginylation can be associated with protein arginine-methylation, which is critical for the proper functioning of proteins in mammals (25) .
Different proteins regulate striated muscle force development. Active force is produced by the molecular motor myosin II when it binds to actin filaments, a process that is fine-tuned by Ca 2+ binding proteins, including different isoforms of troponin and tropomyosin. Passive force is produced mostly by titin molecules, which form spring-like elements that unravel on stretching and increase sarcomere stiffness. Consequently, any posttranslational modification that affects muscle proteins, such as phosphorylation, oxidation, or nitration, affects muscle contraction and force production.
Based on the recently observed effects of arginylation on muscle proteins, the current knowledge of the mechanisms behind muscle contraction, and pilot data collected in our laboratories, this article advances the hypothesis that active and passive force generation are regulated by this form of posttranslational modification. We will present data suggesting that muscle regulation driven by arginylation takes place at the level of myosin-actin interactions and titin molecules, directly influencing the most basic features of muscle contraction.
Background
Arginylation was first discovered in 1963, when a group of investigators observed that proteins can incorporate radioactive amino acids in ribosome-free cell extracts from prokaryotic cells and mammalian tissues (10, 11) . Such translation-independent amino acid incorporation by proteins was linked eventually to a previously unknown posttranslational modification, which in all eukaryotes involves the tRNA-dependent addition of Arginine (Arg). This discovery opened a series of studies leading to the identification of the Arg transfer enzyme (Ate1) (1) .
Although most of the early studies focused on the biochemical aspects of arginylation without gaining extensive insights into its biological function, this posttranslational is now associated with a variety of cellular and physiological processes including cellular stress, aging, liver and nerve regeneration, and protein degradation, to cite a few (14) . In fact, protein arginylation has been recognized as a global protein regulator with functions and pathways that may influence any organ in the animal body. Its importance has been compared with that of protein phosphorylation, another posttranslational modification with global regulatory roles.
Most importantly for this article, recent studies have suggested that protein arginylation is essential for muscle development and contractility (3, 15, 20, 23) . Although studies investigating the role of arginylation in striated muscles are at its infancy, this form of protein regulation may prove essential for contraction and force production, with far-reaching implications for our understanding of muscles in general.
Muscle Development, Structure, and Contractility A key step in discovering the functional role of arginylation in mammalian muscles was the development of knockout (KO) mice lacking the Ate1 enzyme (16) . These full KO mice presented several developmental defects, including severe impairments in the heart structure and contractility (23) , which was an early indication of the key role arginylation plays in striated muscle. Subsequent to the ATE1 −/− model, investigators developed cardiac-specific KO mice, with ATE1 deletion driven by α-myosin heavy chain promoter (αMHC-Ate1), and skeletal muscle-specific KO mice, driven by creatine kinase promoter (Ckmm-Ate1). Interestingly, although the strains presented different phenotypes, they shared a similar feature: they all lead to muscle weakness.
Complete ATE1 KO in mice results in embryonic lethality accompanied by defects in cardiovascular development and angiogenesis. ATE1
−/− embryonic hearts presented ventricular and atrial septal defects as well as thinner atrial and ventricular walls (16, 23) , indicating that arginylation is essential for heart development. Electron micrographs showed delayed myofibril formation, with fewer and more disorganized myofibrils than what would be expected for their development stage. ATE1 KO myofibrils also presented diffused sarcomeric Z-lines and defects in the intercalated disks (23) . All these effects at the structural level imply a weakened heart muscle and suggest a large-scale effect on the functionality and contractility of the heart.
A subsequent study used cardiac-specific ATE1 KO mice driven by αMHC promoter that occurred after cardiomyocyte differentiation and thus was confined largely to the fully developed heart muscle. Such αMHC-Ate1 mice showed no defects in heart septation or myocardium thickness, suggesting that these defects may initiate before heart formation. As a result, these mice survived to adulthood, enabling the study of the direct effects of ATE1 on the contractility of the hearts. Notably, although these mice showed no obvious phenotypic changes at young age, they exhibited high rates of lethality at 6-12 months of age because of the development of age-related dilated cardiomyopathy and thrombosis (15) . These defects were accompanied by ultrastructural abnormalities in the heart muscle (revealed by electron microscopy), which initiated earlier than the dilated cardiomyopathy symptoms and could be observed right after birth. Most importantly for the current article, echocardiographic measurements revealed for the first time impairment in cardiac contractility in the aged αMHC-Ate1 mice. The investigators observed a reduction in the shortening of αMHC-Ate1 hearts, a phenomenon commonly associated with dilated cardiomyopathy. They also revealed a significant reduction in both the active and the passive force in the cardiac myofibrils isolated from these mice (15) .
To investigate the possibility that ATE1 may play a universal role in facilitating normal contractility of striated muscle, the same group of investigators developed skeletal muscle-specific ATE1 KO mice (Ckmm-Ate1). In these mice, unlike αMHC-Ate1 mice, the sarcomere structure was normal suggesting that arginylation is not required for the proper assembly of sarcomeric proteins in skeletal muscle, unlike the heart. Most tellingly, Ckmm-Ate1 mice presented a lower overall force in the hind limb muscles and difficulty of locomotion (3), i.e., muscle weakness induced by the lack of arginylation.
It is intriguing that arginylation has a selective effect on the development of cardiac, but not skeletal muscle. The reason may be the different residues and proteins that are arginylated in these muscles. For instance, the levels of actin arginylation are higher in the developing heart than in skeletal muscles, and additional arginylated sites in actin monomers may be important for filaments alignment. Furthermore, although skeletal muscle titin isoform presented more sites for arginylation than cardiac titin, one site found in the heart is located in the titin serine-threonine kinase domain (C24818). This domain is important for sarcomere formation during myofibrillogenesis, ruling a signaling pathway that senses mechanical load and regulates transcriptional activity in muscle cells (19) . Interestingly, an arginine mutation in the kinase domain (R279W) is related to hereditary myopathy with early respiratory failure (19) , a skeletal muscle disease characterized by muscle weakness and prominent sarcomeric defects including atypical Z-disks, clustering of actin filaments, and disarrangement of filaments (Edstrom et al., 1990).
Subcellular Effects
Studies comparing force production at subcellular levels, ranging from isolated myofibrils to single myosin molecules, advanced our understanding of the effects of arginylation on muscle contractility. Some of these studies used single myofibrils that allow force measurements without the interference of excitation-contraction coupling or Ca 2+ -related mechanisms of activation. Given their small diameter (~1 μm), myofibrils allow precise measurements of the specific force -the force produced during contractions normalized by the myofibril cross-sectional area. Measurements of specific force prevent potential complications arising from changes in muscle size observed in muscular atrophy.
The active and passive forces of myofibrils were measured using an advanced system of atomic force microscopy (AFM) (15) that allows measurements in the scale of a few millinewtons of force. In the heart muscle, myofibrils isolated from αMHC-Ate1 produced approximately 30% less specific force than wild-type (WT) myofibrils during full activation (15) , unequivocally showing that the loss in force observed in the whole muscle is a characteristic of the sarcomeres and thus the contractile proteins (Fig. 1A) . The study was followed by similar experiments performed with skeletal muscle myofibrils, which also showed a substantial decrease in force, although smaller than in cardiac myofibrils, of approximately 20% smaller than WT (3). The smaller decrease in the force observed in skeletal muscle myofibrils when compared with cardiac myofibrils may be associated with the differences observed in muscle structure; in cardiac muscles, the misalignment of the contractile filaments may contribute significantly to an impairment of force.development during activation (K act ), force redevelopment after a shortening-stretching maneuver (K tr ), and relaxation (K rel ) of activated myofibrils. These parameters are putative indicators of myosin cross-bridge kinetics because they are associated closely with the transitions of cross-bridges between different states while attached to actin filaments. K act and K tr are indicative of cross-bridges transitioning from a weakly bound state to a strongly bound state, culminating with force generation. K rel is indicative of cross-bridge detachment from actin on reduction of Ca 2+ concentration. All these parameters were lowered in KO mice (3, 15) (Fig. 1) . Because Ca 2+ activation is maintained maximal during these experiments, the results suggest that the myosin-actin interactions were affected in the KO mice likely by a lower rate of cross-bridges transitioning from the weakly bound to the strongly bound state and a lower detachment rate from actin. The results suggest a reduction in the number of cross-bridges being formed because of the lack of arginylation (3).
Although cross-bridge kinetics can be affected by different mechanisms, it is governed mostly by the molecular motor myosin II. Thus, the myofibril experiments were followed by experiments performed with isolated myosin filaments interacting with actin filaments. Such preparation enables the investigators to determine if the reduction of myofibril force directly arises from posttranslational modification on the myosin-actin level. After filament attachment, Ckmm-Ate1 myosin filaments presented a significant reduction in active force when compared with WT filaments, showing that the force is reduced because of a decreased force produced by individual myosin molecules during attachments with actin ( Fig. 1C-D) . The results suggest that arginylation is essential for a normal myosin-actin cycle. Most strikingly, after rescuing the filaments with a specific rearginylation assay, the filaments were able to restore the force to the control level (Fig. 1D) (3) .
Finally, studies also have showed that the lack of arginylation affects the passive force development in conditions where the myofibrils were stretched sequentially at low Ca 2+ concentrations, i.e., no activation of the myosin-actin system (15) . At the sarcomeric level, passive force is developed mainly by titin, a giant multifunctional protein that spans the halfsarcomere from the Z-lines to M-lines. In the I-band, titin forms spring-like domains that synchronously work to adjust the tension within each sarcomere in response to its length. As the sarcomere stretches from slack to long lengths, the Ig segments within this region start to develop force first, followed by the E-rich segment named PEVK. The PEVK domains start to develop force at long sarcomere lengths (28) . In cardiac muscles, the spring-like domain called N2B follows PEVK and produces force when the sarcomere reaches longer lengths (6) . In a recent study, passive force development was found to be impaired in Ckmm-ATE1 myofibrils. Using AFM measurements in single myofibrils and a newly designed system to measure passive force in single sarcomeres, investigators found a decrease in both viscoelastic and elastic properties of titin. This reduction was independent of titin phosphorylation (20) , and, thus, must be associated with a direct effect of arginylation on titin properties. Figure 1 . Experimental studies investigating the role of arginylation in force production. A. Myofibrils isolated from cardiac muscles lacking arginylation (red trace) present a reduced force when compared with myofibrils isolated from wild-type (WT) mice (black trace). The decrease in force is accompanied by a decrease in the rate of force development on activation (K act ), the rate of force redevelopment after an imposed shortening during activation (K tr ), and the rate of relaxation (K rel ). B. Electron microscopy reveals that, in cardiac muscles, lack of arginylation leads to morphological changes (bottom panel) when compared with WT (upper panel) including filament misalignment and ruptured Z-discs (arrows). C. Isolated filaments of skeletal muscles extracted from muscles lacking arginylation (red trace) produce less force than filaments isolated from WT muscles. D. The force produced by isolated filaments of myosin and actin isolated from knockout (KO) mice lacking arginylation is restored fully after rearginylation (Re-Arg).
Arginylation Sites in Sarcomeric Proteins
The results from mechanical studies with animals, isolated myofibrils, single sarcomeres, and filaments support the hypothesis that arginylation directly affects the proteins responsible for active and passive force (Fig. 2) . Recent developments of mass spectrometry methods have been critical to identify arginylation sites in different proteins (30, 31) . Although the sites are not similar in cardiac and skeletal muscles (Table) , most of the proteins targeted for arginylation are related directly to sarcomere structure, integrity, and contractile activity including myosin heavy chains, myosin light chains, actin, α-actinin, titin, tropomyosin, troponin T, and myosin-binding protein-C.
Myosin heavy chain (MHC) was one of the proteins arginylated in both skeletal and cardiac muscles. MHC presents the greatest number of target residues within the contractile machinery including specific sites associated with the rod and tail domain of myosin responsible for self-association, the integrity of actomyosin assemblies, and myosin conformation during the cross-bridge cycle. The lack of arginylation in these sites of myosin may be associated directly with the results obtained in the mechanical studies with myofibrils and filaments:
an impairment of myosin-actin interactions and alterations in myofibrils force development and relaxation. Myosin light chains (MLC) play a regulatory role in skeletal and cardiac muscles, important for the regulation of contractility. Phosphorylation of MLC has been associated with augmented mobility of the myosin heads from the thick filament backbone, increasing the probability of myosin-actin attachments and consequently the probability of myosin-actin interactions (26, 27) .
The actin filament is a two-strand coiled coil polymer of actin globules (G-actin) assembled with different accessory proteins. Actin is arginylated in the skeletal muscle of adult mice and in the developing heart on four sites (3, 23) . Two of these residues are accessible only before G-actin is incorporated into the polymer and may have important roles for actin polymerization (23) . The differences in arginylated sites between cardiac and skeletal actin may relate to the structural differences found between cardiac and skeletal muscle sarcomeres.
Tropomyosin and troponin form the thin-filament regulatory complex, inhibiting the actomyosin interaction in response to the fluctuation of cytoplasmic Ca 2+ levels. Tropomyosin is a rod-shaped protein that interacts with the actin filament. One tropomyosin molecule interacts with seven actin monomers Figure 2 . Diagram of a half-sarcomere and the main proteins that are targeted by arginylation that affect contractility and passive forces in striated muscles. These proteins have specific functions. A. Myosin-binding protein C protein C (MyBP-C) is an accessory protein responsible for regulation of myosin head displacements and possibly strengthening of the thick filament backbone. B. The thin filament (actin, tropomyosin, and troponin) and myosin, key proteins related to the cross-bridge formation and regulation, are arginylated. C., D. Titin is arginylated in the A-band region, associated with the myosin(G-actin) in a row and with the other two tropomyosin molecules through head-to-tail contact. Troponin T is one of the components of the troponin complex, responsible for the affinity of the troponin complex to tropomyosin and for its fixation on the actin filament (22) . Altogether, the troponin complexes and the tropomyosins form a long regulatory strand component that runs the grooves of the whole actin filament, so that each regulatory unit is composed of one troponin complex, one tropomyosin, and seven actin monomers. Sites for arginylation were found on tropomyosin and troponin T in the cardiac muscle and on two different isoforms of troponin T in the skeletal muscle (Table) , suggesting that arginylation regulates properties and functions of the tropomyosin/troponin complex.
α-Actinin is arginylated in both cardiac and skeletal muscles. In cardiac muscle, the site for arginylation on α-actinin is located in a short linker region that may be important for dimerization. In skeletal muscle, the arginylated residues are located within the second spectrin-like repeat, which is part of the α-actinin rod, an important area for protein-protein binding and one of the essential areas for titin anchoring (5) . α-Actinin is a highly conserved actin-binding protein that cross-links antiparallel actin filaments from adjacent sarcomeres on the Zdisks. α-Actinin is a homodimer with four spectrin-like repeats that form the central α-actinin rod. There is an actin-binding domain in the N-terminal and a calmodulin-like domain with two pairs of EF hand motifs in the C-terminus flanking the rod (5, 24) . α-Actinin has several areas for protein-protein binding with important implications for Z-disk assembly and sarcomere function (32) . A weakening of the titin-myosin and/or titin-α-actinin binding may impair titin elongation during sarcomere stretch and consequently the passive forces.
Myosin-binding protein C protein C (MyBP-C) is an important regulatory protein found in the thick filament of striated muscles. It interacts with myosin molecules, titin, and actin. Studies have linked MyBP-C to cross-bridge formation, regulation of myosin head movements, and possibly strengthening of the thick filament backbone (reviewed in (4,29) ). MyBP-C is composed mainly of immunoglobulin and fibronectin domains, with a proline/alanine-rich region and a MyBP-C-specific motif (M-domain). The arginylation site (E162) found in the skeletal muscle MyBPC is located in the M-domain (3) . It has been shown that the M-domain is an important area for the interaction of the myosin filament with the actin filament, and atomic force microscopy studies have shown that the M-domain has an elastic structure that unfolds at low forces (8, 13) .
Titin is the main protein responsible for passive force development in muscle fibers and is arginylated in several sites in both cardiac and skeletal muscles. The lack of arginylation in titin might be directly responsible for the decrease in passive force observed in KO myofibrils, caused by a decrease in titin stiffness on muscle elongation. It is still unclear how this impairment occurs because all the sites arginylated in titin are located in the nonextensible part of the molecule, the A-band region (20) . It is possible that titin anchoring in either side (or both) of the I-band is impaired in the KO muscles. In one side, titin closely interacts with the myosin filament and anchors in the M-line (2, 7, 9, 21) . This interaction starts very early in the muscle development and has important structural functions. It also is possible that the connection between titin and myosin is impaired in muscles lacking arginylation. Finally, the N-terminus of titin binds to the entire length of the Z-line. In this area, titin molecules from adjacent sarcomeres overlap through titintelethonin and titin-α-actinin binding (5, 32, 33) . Although skeletal muscle titin isoform presented more sites for arginylation than cardiac titin, one site found in the heart is located in the titin serine-threonine kinase domain (C24818). During myofibrillogenesis, this kinase domain is important for sarcomere formation, driving a signaling pathway that senses the cell mechanical load and regulates transcriptional activity in the cells (19) .
SUMMARY Toward a Comprehensive Model for Arginylation-Mediated Muscle Regulation
The roles of the residues targeted for arginylation in the sarcomeric proteins are not clear yet. However, based on the emerging evidence linking muscle functions and arginylation and the well-known global effects of arginylation on proteins, we hypothesize the following (Fig. 2): 1. Arginylation affects cardiac muscle development by facilitating proper myofibril formation and arrangement. It strengthens protein binding within the sarcomere, so that the myofilaments are stable and aligned. Hence, cardiac myofibrils lacking arginylation may present protein-binding defects, resulting in misalignment of filaments, diffuse Z-disks, and asymmetric sarcomeres.
2. ATE1 targets key amino acid residues in proteins of both cardiac and skeletal muscles that are essential for myofibril active and passive force production. Specifically, the arginylation of MHC, actin and titin are essential for proper muscle contractility, myosinactin interactions, and the cross-bridge cycle.
The broad number of proteins that are targeted by arginylation within muscle cells and their key roles suggest that this posttranslational modification is involved in several physiological processes that are important for muscle function. Studies have shown that ATE1 levels achieve their highest during middevelopment (17) and decline in different tissues with age (18) . Therefore, any potential reduction in posttranslational arginylation of muscle proteins may be related to muscle degenerative processes, such as cardiomyopathies and muscular weakness that occur with aging. The implications of muscle arginylation may have far-reaching consequences to normal physiology and disease.
